Sanara MedTech Inc. — Director's Dealing 2020

Feb 11, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Sanara MedTech Inc. (SMTI)
CIK: 0000714256
Period of Report: 2020-02-07

Reporting Person: CGI Cellerate RX, LLC (10% Owner)
Reporting Person: Catalyst Rochal, LLC (10% Owner)
Reporting Person: Gurasich Bradley J. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-07	Common Stock	C	2273630	—	Acquired	2273630	Direct
2020-02-07	Common Stock	C	179101	$9	Acquired	2452731	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-07	Series F Convertible Preferred Stock	$	C	1136815	Disposed		Common Stock (2273630)	Direct
2020-02-07	5% Convertible Promissory Note	$9	C		Disposed	2021-03-01	Common Stock (179101)	Direct

Footnotes

F1: The Series F Convertible Preferred Stock was convertible into Common Stock at any tme on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for1 in accordance with the terms of the Series F Convertible Preferred Stock.

F2: Reflects shares of Common Stock owned of record by CGI Cellerate RX, LLC, which is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Gurasich is a manager of Catalyst Rochal, LLC. By virture of these relationships, Mr. Gurasich, Catalyst Rochal, LLC and CGI Cellerate RX, LLC may be deemed to share voting and dispositive control over the Common Stock. Mr. Gurasich and Catalyst Rochal, LLC disclaim beneficial ownership of any Common Stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein.

F3: The 5% Convertible Promissory Note in the principal amount of $1,500,000 was convertible into Common Stock at any time prior to maturity at an initial conversion price of $0.09 per share. As a result a 1-for-100 reverse stock split of the Common Stock on May 10, 2019, the conversion price was automatically adjusted to $9.00 per share in accordance with the terms of the Promissory Note. The terms of the Promissory Note also provided for the right of conversion of any accrued and unpaid interest. The amount of $111,911 in accrued interest was also converted into 12,434 shares of Common Stock at $9.00 per share.